All In MedTech

Device Trial Radar · NCT05368259

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

A Prospective, Open-Label, Multi-Center, Randomized, Pivotal Safety and Efficacy Study of the Allurion Gastric Balloon System + Moderate Intensity Lifestyle Modification Therapy Program vs. Moderate Intensity Lifestyle Modification Therapy Program for the Treatment of Adults With Obesity

Last checked: Nov 20, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

May 12, 2022

Primary completion

Nov 1, 2024

Study completion Mar 1, 2025

Sponsor

Lead sponsor
Allurion TechnologiesNot on our public-company list
Sponsor type
Industry
First posted
May 10, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective for this clinical study is to provide FDA with clinical evidence regarding the effectiveness and safety of the AGBS + moderate intensity lifestyle modification therapy program, indwell time of the AGBS inside the stomach, and outcomes at 48 weeks.

Conditions

  • Obesity

Interventions

  • AGBSDevice

    The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder Rate (RR) dichotomized at 5% TBWL at 48 weekTime frame: 48 weeks
  2. %TBWL is significantly greater than Control Group mean %TBWL at 48 weeksTime frame: 48 weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Cedars-Sinai

    Los Angeles, California

  • University of Colorado, Anschutz Health and Wellness Center

    Aurora, Colorado

14 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.